Introduction
Acute Basophilic Leukemia is an uncommon hematological malignancy, currently categorized by the 2008 World Health Organization (WHO) classification as a particular subtype of unspecified acute myeloid leukemia (AML), often associated with an aggressive clinical course and dismal prognosis [1] . Complications related to high histamine release, including skin rash, peptic ulcer, gastrointestinal bleeding, anaphylaxis and respiratory symptoms have been reported [2, 3] . Meticulous morphological, cytochemical, immunophenotypic, molecular, and cytogenetic studies are required to fully characterize acute basophilic leukemia. Differential diagnosis includes other myeloid neoplasms associated with basophilia, namely AML with t(6;9)(p23;q14), acute promyelocytic leukemia with basophilic differentiation, blastic transformation of chronic myelogenous leukemia, primary myelofibrosis, or rare acute lymphoblastic leukemia cases with prominent cytoplasmic granules [1, 4] . Noteworthy, even though multiple chromosomal abnormalities have been reported involving chromosomes 1, 2, 6, 7, 8, 11, 12, 16, 17, 19, 21 and X, no recurrent cytogenetic or molecular anomalies have been described in acute basophilic leukemia patients [3, [5] [6] [7] [8] [9] [10] [11] [12] [13] . Acute basophilic leukemia management remains poorly defined, relying on cytarabine and anthracycline-based induction regimens, palliative cytoreductive treatment, targeted therapies (tyrosine kinase inhibitors) or allogeneic stem cell transplant in selected cases [7, 14] . Shortened disease free survival (DFS) or refractory disease are common among acute basophilic leukemia patients [7, 14] .
Case report:
A 63-year-old female patient with a medical history of diabetes, hypertension, bronchial asthma since the age of 35, and diagnosed with non-Hodgkin lymphoma at age 36, for which she had previously received chemo-and radiotherapy, was admitted for fatigue and exertional dyspnea. Physical examination was unremarkable, with no cutaneous lesions documented. Asthma control had been previously achieved with inhaled long acting bronchodilators and corticosteroids, with no identifiable exacerbations within the 12 months preceding admission to our clinic. Laboratory findings revealed a hemoglobin level of 6.7 g/dl, 66x10 9 /L platelets, 18x10 9 /L leukocytes, 1.2x10 9 /L neutrophils, 0.9x10 9 /L basophils and 68% agranular blasts with basophilic cytoplasm. Bone marrow (BM) investigation revealed hypercellularity with 70% infiltration with ambiguous lineage agranular blasts, some resembling proerythroblasts and others with cytoplasmic vacuoles. The following features of bone marrow dysplasia were present in 10% of the examined nucleated cells: neutrophil hypogranularity, nuclear erythroid dysplasia and megakaryocyte hypolobulation (Figure 1 ). Flow cytometry immunophenotyping confirmed the basophilic nature of the blasts and also revealed the presence of a minor subclone with early mastocyte lineage commitment (Table  1 ) (Figure 2 ).
Molecular testing for FLT-3 ITD (FMS-like tyrosine kinase receptor-3-internal tandem duplication) was positive. CBFB-MYH11, RUNX1-RUNX1T1, PML-RARα, FLT3 D835 mutation, and NPM 1 were negative. Conventional cytogenetic examination using GTG banding revealed a complex karyotype, with multiple numerical and structural aberrations (14 metaphases with structural anomalies consisting of t(1;4) (p35;q35), del(5)(q31->qter), t(5;20)(p15;p13) and 17 metaphases with numeric anomalies: 11 metaphases with hyperdiploidy (47-50 chromosomes) and 6 metaphases with hypodiploidy. t (9, 22) or t(6,9) were not identified. del(5)(q31->qter) was confirmed by interphase fluorescence in situ hybridization (FISH) testing ( Figure 3 ). No 11q23 rearrangements were described.
A diagnosis of therapy related FLT-3-ITD positive acute basophilic leukemia was established, based on the medullary infiltrate phenotype and on the cytogenetic and molecular exclusion of other basophilia-associating myeloproliferative syndromes. Ultrastructural characterization of basophilic blasts by electron microscopy was not available.
Within 72 hours following admission, the patient developed symptoms of progressive respiratory failure, with bronchospasm and wheezing. In parallel, a threefold increase of leukocytes (47x10 9 L) was recorded. The patient remained afebrile and C reactive protein was only mildly increased (10 mg/L, normal range: 0 to 1 mg/L), underlining the unlikelihood of pulmonary infection. Thoracic computed tomography revealed bilateral ground glass infiltrates and ruled out pulmonary embolism.
Furthermore, broad spectrum antibiotherapy and a short empirical course of Voriconazole led to no respiratory improvement. Taking into account the low probability of pulmonary infection and the temporal concurrence of progressive leukocytosis and respiratory failure with bronchospastic features in a patient with previously controlled asthma, we considered the diagnosis of non-cardiogenic pulmonary edema secondary to pulmonary leukostasis. Normal serum hista- mine and tryptase levels were considered unreliable, as they were measured after corticotherapy initiation. Consequently, standard "3+7" (Idarubicin 12 mg/m 2 intravenously for three days and cytarabine 100 mg/m 2 in continuous intravenous infusion for seven days) induction therapy was initiated. Within one hour after chemotherapy initiation the patient presented grade 2 cytokine release syndrome (hypotension, fever, chills, profuse sweats, rash and bronchospasm exacerbation).
Under chemotherapy and intravenous methylprednisolone, bronchodilators and histamine receptors 1 and 2 blockade the respiratory symptoms and bronchospasm gradually improved over the next 72 hours.
On day +18 post induction, the hemogram showed 7.2x10 9 /L leukocytes and peripheral blood smear examination revealed blast cells, attesting refractory disease. Within 24 hours the respiratory symptoms present on diagnosis reoccurred. A re-induction course of 500 mg cytarabine for three days was attempted, but the patient died due to progressive respiratory failure.
Discussion
Acute basophilic leukemia remains a poorly defined entity, due to lack of standardized diagnostic criteria, treatment regimens, and scarcity of case reports. According to the 2008 WHO classification [1] and its 2016 revision [15] , acute basophilic leukemia diagnosis requires specific morphological and immunophenotypic criteria and exclusion of other hematological basophilia-associating neoplasms. No characteristic recurrent cytogenetic or molecular abnormalities have been defined to date.
It should be noted that some acute basophilic leukemia cases reported before 2008 do not fit the current WHO definition and represent in fact blastic phases of chronic myeloid leukemia presenting with significant basophilia [16] .
FLT-3-ITD mutation occurs in about 30% of adult AML cases and it is correlated with reduced DFS and overall survival [17, 18] . FLT3-ITD mutation is a common finding in AML patients with t(6:9)(p23:q34) (78% of cases) [1] , alongside BM dysplasia and a complex karyotype. In our case, the diagnosis of acute basophilic leukemia with mutated FLT3-ITD is strongly supported by flow cytometry data and cytogenetic studies. Furthermore, to the best of our knowledge, this is the first reported case of FLT3-ITD positive acute basophilic leukemia, doubled by a complex, also previously unreported karyotype.
Additionally, the patient's history of chemoand radio-treated non Hodgkin lymphoma and multilineage BM dysplastic features suggest a possible preceding myelodysplastic syndrome. Although BM dysplastic features were present, they did not surpass the 50% threshold necessary for the diagnosis of AML with myelodysplasia-related features. Despite the late onset of the disease relative to the previous lymphoma-targeted chemotherapy, the presence of chromosome 5 anomalies is suggestive for therapy-related acute basophilic leukemia. Furthermore, this case features a rare presentation of hypercellular acute basophilic leukemia precipitating phenomena of respiratory failure in a patient with previously controlled asthma.
The extent to which asthma history might have contributed to a leukemia phenotype shift towards the basophil lineage is difficult to evaluate. Literature cites a case of mixed lineage eosinophil-basophil acute leukemia in a young female patient associating asthma [19] . T helper 2 lymphocytes trafficking from airways of asthmatic patients to the BM apparently induce up-regulation of interleukin-5 (IL-5) receptors on CD34+ progenitors, thus altering normal hematopoiesis and favoring IL-5 mediated expansion of eosinophil and basophil precursors [20] . However, it is virtually impossible to assess whether IL-5-induced modifications in the BM microenvironment of asthma patients might contribute to leukemogenesis and the subsequent basophilic and mastocytic differentiation in this particular case.
The temporal concurrence of respiratory symptoms and progressive leukocytosis strongly suggest intricate phenomena of pulmonary leukostasis and capillary leak syndrome. Ground glass opacities sparing the lung bases and the subpleural space are evocative of non-cardiogenic pulmonary edema. Pulmonary leukostasis requires endothelial cell activation and expression of various adhesion molecules by the leukemic blasts, including CD56, irrespective of the absolute leukocyte count [21, 22] . In this case, CD56 expression on basophilic blasts might have specifically facilitated the development of leukostasis. Spontaneous or post therapeutic worsening of respiratory failure in patients with pulmonary leukostasis has been previously cited in hypercellular myelomonocytic leukemias [23, 24] .
Moreover, bronchospasm exacerbation alongside hypotension and rash following chemotherapy initiation strongly suggest the implication of vaso-and broncho-active mediators released upon lysis of basophilic blast cells. Pulmonary damage in myelomonocytic leukemias associating eosinophilia has been linked to eosinophil degranulation [25, 26] , emphasizing the likelihood of a similar mechanism in acute basophilic leukemia. Consequently, steroid premedication and double histamine receptor blockade was initiated and succeeded to limit the impact of histamine related complications. Ultimately, reappearance of respiratory distress upon emergence of refractory disease and subsequent basophil proliferation further indicate the role of tumor progression and cytokine release in the pathogenesis of pulmonary edema and leukostasis.
Previously published data have certified the existence of certain clonal relationship between myeloid blasts and BM mast cells in an AML patient [27] . The presence of two different AML clones, identified by differential expression of HLA-DR, CD117 and CD203c suggest a putative common origin of these subclones, i.e. a common malignant basophil-mastocyte progenitor, even though the existence of its normal counterpart in human hematopoiesis has yet to be demonstrated [28] .
Conclusion
Acute basophilic leukemia is a very rare AML subtype whose diagnosis poses a real challenge. Furthermore, acute basophilic leukemia management is still unstandardized and one should always be aware of the potential of the disease to lead to life-threatening histamine-driven pulmonary, cardiovascular, digestive, and skin complications. Spontaneous or post chemotherapy respiratory distress should raise suspicion of pulmonary capillary leak induced by basophil lysis or degranulation. Dou-ble histamine receptor blockade, steroid therapy and chemotherapy initiation are recommended in such cases, as well as empirical antibiotherapy, since infection cannot be definitely ruled out.
Noteworthy, normal serum levels of histamine and tryptase should not discourage therapy in the setting of high clinical suspicion of histamine-driven complications.
